These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4087685)

  • 21. Evaluation of a routine method for determination of calcium oxalate crystal growth inhibition in diluted urine samples.
    Tiselius HG; Fornander AM
    Clin Chem; 1981 Apr; 27(4):565-8. PubMed ID: 7471423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium oxalate crystalluria: crystal size in urine.
    Elliot JS; Rabinowitz IN
    J Urol; 1980 Mar; 123(3):324-7. PubMed ID: 7359628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulatory effect of the 23-kD calcium oxalate monohydrate binding protein on calcium oxalate stone formation during oxalate stress.
    Asokan D; Kalaiselvi P; Varalakshmi P
    Nephron Physiol; 2004; 97(1):p23-30. PubMed ID: 15153748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin.
    Worcester EM; Sebastian JL; Hiatt JG; Beshensky AM; Sadowski JA
    Calcif Tissue Int; 1993 Oct; 53(4):242-8. PubMed ID: 8275352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary crystal growth: effect of inhibitor mixtures.
    Werness PG; Bergert JH; Lee KE
    Clin Sci (Lond); 1981 Oct; 61(4):487-91. PubMed ID: 6169479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis.
    Coe FL; Nakagawa Y; Asplin J; Parks JH
    Miner Electrolyte Metab; 1994; 20(6):378-84. PubMed ID: 7783700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleation of calcium oxalate crystals by albumin: involvement in the prevention of stone formation.
    Cerini C; Geider S; Dussol B; Hennequin C; Daudon M; Veesler S; Nitsche S; Boistelle R; Berthézène P; Dupuy P; Vazi A; Berland Y; Dagorn JC; Verdier JM
    Kidney Int; 1999 May; 55(5):1776-86. PubMed ID: 10231440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates.
    Gupta M; Tuncay OL; Valderrama E; Smith AD
    J Endourol; 1997 Feb; 11(1):1-4. PubMed ID: 9048290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine.
    Edyvane KA; Hibberd CM; Harnett RM; Marshall VR; Ryall RL
    Clin Chim Acta; 1987 Aug; 167(3):329-38. PubMed ID: 3621616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary crystallization inhibitors do not prevent crystal binding.
    Schepers MS; van der Boom BG; Romijn JC; Schröder FH; Verkoelen CF
    J Urol; 2002 Apr; 167(4):1844-7. PubMed ID: 11912445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation.
    Drach GW; Thorson S; Randolph A
    Trans Am Assoc Genitourin Surg; 1979; 71():62-6. PubMed ID: 161827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load.
    Guerra A; Allegri F; Meschi T; Adorni G; Prati B; Nouvenne A; Novarini A; Maggiore U; Fiaccadori E; Borghi L
    Clin Chem Lab Med; 2005; 43(6):585-9. PubMed ID: 16006253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uropontin in urinary calcium stone formation.
    Hoyer JR
    Miner Electrolyte Metab; 1994; 20(6):385-92. PubMed ID: 7783701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.
    Shiraga H; Min W; VanDusen WJ; Clayman MD; Miner D; Terrell CH; Sherbotie JR; Foreman JW; Przysiecki C; Neilson EG
    Proc Natl Acad Sci U S A; 1992 Jan; 89(1):426-30. PubMed ID: 1729712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro.
    Ryall RL; Harnett RM; Marshall VR
    Clin Chim Acta; 1981 May; 112(3):349-56. PubMed ID: 6263523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crystal agglomeration is a major element in calcium oxalate urinary stone formation.
    Kok DJ; Papapoulos SE; Bijvoet OL
    Kidney Int; 1990 Jan; 37(1):51-6. PubMed ID: 2299809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid method of measuring the inhibition of calcium-oxalate monohydrate growth in urine.
    Baumann JM; Ackermann D; Affolter B
    Urol Res; 1990; 18(3):219-22. PubMed ID: 2396351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pH on the urinary inhibition of calcium oxalate crystal growth.
    Tiselius HG
    Br J Urol; 1981 Oct; 53(5):470-4. PubMed ID: 6793122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bikunin prevents adhesion of calcium oxalate crystal to renal tubular cells in human urine.
    Ebisuno S; Nishihata M; Inagaki T; Umehara M; Kohjimoto Y
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S436-40. PubMed ID: 10541279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.